

PROTEIN MEDICINES FOR LIFE

**MANAGEMENT TEAM**

**Lewis (Rusty) Williams, MD, PhD**  
Executive Chairman, Founder,  
President and CEO

**W. Michael Kavanaugh, MD**  
Sr. VP Research and Development

**Kevin Baker, PhD**  
VP Preclinical Development

**Marc Belsky**  
VP Finance

**Lauretta Cesario**  
VP Human Resources

**Jeffrey Finer, MD, PhD**  
VP Discovery

**Harold Keer, MD, PhD**  
VP Clinical Development

**Aron Knickerbocker**  
VP Business Development

**Francis Sarena**  
VP General Counsel & Secretary

**Brian Wong, MD, PhD**  
VP Immunology and Discovery  
Research

**BOARD OF DIRECTORS**

**Brian Atwood**  
Versant Ventures

**Franklin Berger**  
Independent Biotechnology Research  
Analyst

**Brook Byers**  
Kleiner Perkins Caufield Byers

**Fred Cohen, MD, PhD**  
TPG Ventures

**Lee Douglas**  
Co-founder, Cor Therapeutics

**Peder Jensen, MD**  
**Mark McDade**

COO and EVP, UCB SA  
**Lewis T. (Rusty) Williams, MD, PhD**  
Executive Chairman, Founder,  
President and CEO

**SCIENTIFIC ADVISORY BOARD**

**Stanley Cohen, MD**  
Stanford University Medical Center

**Joseph Goldstein, MD**  
UT Southwestern Medical School

**C. Ronald Kahn, MD**  
Joslin Diabetes Center

Harvard Medical School  
**Robert Lefkowitz, MD**

Duke University Medical Center  
**Ronald Levy, MD**

Stanford University Medical Center  
**Daniel Von Hoff, MD**

Translational Genomics Research  
Institute


**Arthur Weiss, MD, PhD**  
UC San Francisco

**Employees: 125**


Five Prime Therapeutics, Inc. is a clinical-stage, privately-held biotechnology company discovering and developing innovative protein and antibody therapeutics. We focus on protein and antibody drugs as they tend to be target-specific with strong safety profiles and therefore often have higher probabilities of success. The Company applies a novel approach to drug discovery by integrating proprietary screening tools with FivePrime's human protein library, the largest and highest quality collection of its kind in the world, containing the majority of the secreted proteins and extracellular domains of receptors. We developed the **Rapid in Vivo Protein Production System (RIPPS<sup>SM</sup>)**, which is the first system that enables high throughput expression of proteins to identify, test and validate product candidates directly in animal models of human disease. RIPPS achieves pharmacologically relevant protein levels in the animal's circulation within days, without the need for purifying recombinant protein, historically a rate-limiting process. Our clinical areas of focus are oncology and immunologic disease. We have attracted seasoned investors, respected development partners and industry thought leaders.

**PRODUCTS**

We have a pipeline of first-in-class compounds and novel proteins that address significant therapeutic markets. FivePrime's most advanced drug candidate, FP1039, is in Phase 2 development. It is a first-in-class inhibitor of the Fibroblast Growth Factor (FGF) pathway for treatment of cancer. In oncology, the FGF pathway has been validated by decades of research and thousands of scientific publications. FP1039 has shown activity in multiple cancer models, with an acceptable safety profile. Additionally, FivePrime's discovery of a completely new cytokine, IL-34, led to the development of its IL-34 inhibitor, which may have use in multiple sclerosis, rheumatoid arthritis and other autoimmune diseases. The IL-34 inhibitor targets the innate immune system and has a differentiated mechanism of action from other drugs. It is active in preclinical models and biomarkers have been identified that may guide dosing and patient selection. A Phase 1 trial is planned next year. In addition, a rapidly growing number of promising pre-clinical compounds are emerging from this discovery engine to fill the pipelines of FivePrime and our collaborators.



**PIPELINE & THERAPEUTIC PROGRAMS**



\* Human Genome Sciences has acquired rights to develop and commercialize FP-1039 in the U.S., EU and Canada. FivePrime retains rights in the rest of world.

**PARTNERING**

FivePrime has entered into an agreement to develop and commercialize FP1039 with Human Genome Sciences, Inc. in the United States, Canada and the EU. FivePrime has retained co-promotion rights to the US and full rights to develop and commercialize FP1039 in the rest of world territories, including Asia.

FivePrime has established significant collaborations for the discovery of innovative biologics in specific therapeutic areas with several leading pharmaceutical companies, including Pfizer, Centocor and GlaxoSmithKline. Our partnerships have resulted in a combination of upfront cash payments and equity investments in FivePrime. As a result, the company is financially well-positioned to execute on

its strategy. Depending on clinical success, these collaborations will also afford FivePrime future milestone and royalty payments. For more information on these opportunities, please contact [business.development@fiveprime.com](mailto:business.development@fiveprime.com)